Equitable Trust Co. Purchases 84 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Equitable Trust Co. increased its position in ICU Medical, Inc. (NASDAQ:ICUI) by 1.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 5,297 shares of the medical instruments supplier’s stock after buying an additional 84 shares during the period. Equitable Trust Co.’s holdings in ICU Medical were worth $822,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Allworth Financial LP boosted its holdings in ICU Medical by 100.0% in the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 100 shares during the period. Venturi Wealth Management LLC boosted its holdings in ICU Medical by 1,510.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 302 shares during the period. Point72 Hong Kong Ltd bought a new position in ICU Medical in the 3rd quarter worth $72,000. GAMMA Investing LLC boosted its holdings in ICU Medical by 83.6% in the 3rd quarter. GAMMA Investing LLC now owns 571 shares of the medical instruments supplier’s stock worth $104,000 after buying an additional 260 shares during the period. Finally, Greenleaf Trust purchased a new stake in ICU Medical in the 3rd quarter worth $207,000. Institutional investors own 96.10% of the company’s stock.

ICU Medical Stock Up 2.0 %

Shares of NASDAQ ICUI opened at $159.78 on Tuesday. The firm’s 50-day moving average price is $160.70 and its 200-day moving average price is $164.00. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The stock has a market capitalization of $3.91 billion, a price-to-earnings ratio of -34.96 and a beta of 0.63. ICU Medical, Inc. has a 12-month low of $93.36 and a 12-month high of $196.26.

Insider Activity

In related news, COO Christian B. Voigtlander sold 1,962 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $169.08, for a total value of $331,734.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director David C. Greenberg sold 972 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total transaction of $153,682.92. Following the completion of the sale, the director now directly owns 5,037 shares in the company, valued at $796,400.07. This trade represents a 16.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 17,737 shares of company stock worth $2,879,752. 6.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have commented on ICUI. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research note on Wednesday, November 13th. Jefferies Financial Group upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target on the stock in a research note on Wednesday, December 11th. Finally, KeyCorp boosted their price target on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $199.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.